Regeneron and CytomX extend cancer therapy partnership to $4bn deal

Conditionally activated bispecific antibody cancer therapiesPositive

AI Analysis

Summary

Regeneron Pharmaceuticals and CytomX have expanded their research and licensing partnership for conditionally activated bispecific antibody cancer therapies in a $4 billion deal.

Importance:7/10

Sentiment:

0.60

PartnershipLicensingBispecific antibodiesOncologyM&A

Related Companies

$REGN $CTMX

Read the original article

Published by Pharmaceutical Technology on June 4, 2026 8:21 AM

Read Original